deltatrials
Unknown PHASE1/PHASE2 NCT00003064

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Phase I-II Study of Tandem Cycles of High Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Support in Women With Persistent, Refractory or Recurrent Advanced (Stage III or IV), Epithelial Ovarian Cancer

Sponsor: Herbert Irving Comprehensive Cancer Center

Conditions Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer
Interventions carboplatin etoposide phosphate filgrastim paclitaxel peripheral blood stem cell transplantation thiotepa topotecan hydrochloride
Updated 5 times since 2017 Last updated: Jan 3, 2014 Started: Jan 31, 1997

A PHASE1/PHASE2 clinical study on Fallopian Tube Cancer and Ovarian Cancer, this trial is ongoing. The trial is conducted by Herbert Irving Comprehensive Cancer Center and has accumulated 5 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE1_PHASE2

    First recorded

Jan 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Herbert Irving Comprehensive Cancer Center
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States